iGene Applies for Phase 1/2a Clinical Trial Plan of COVID-19 Vaccine Booster

[Asia Economy Reporter Minji Lee] iGene announced on the 5th that it has applied for a Phase 1/2a clinical trial plan to verify the safety, tolerability, and immunogenicity of its mRNA-based COVID-19 vaccine (EG-COVID) booster shot in Australia.

The company stated, "After completing Phase 1 of the Phase 1/2a clinical trial in Australia, Phase 2a, which will be conducted on 100 subjects, is planned to take place in Australia and the Republic of South Africa." It added, "We plan to apply for the clinical trial plan in the Republic of South Africa as soon as possible." Furthermore, it explained, "Depending on the evaluation results of safety, tolerability, and immunogenicity confirmed during this clinical process, we plan to proceed to the next phase of clinical trials."